Why is selecting the appropriate probe size (M‑probe versus XL‑probe) important when performing Fibroscan transient elastography?

Why Choosing the Appropriate Fibroscan Probe Size is Critical

Selecting the correct probe size (M-probe versus XL-probe) is essential because using the wrong probe leads to measurement failures, unreliable results, and inaccurate liver stiffness values that can misclassify disease severity—directly impacting clinical decisions about treatment, surveillance, and prognosis.

The Core Problem: Obesity and Measurement Failure

The standard M-probe has significant limitations in overweight and obese patients, which represent a large proportion of patients with chronic liver disease, particularly those with NAFLD. In patients with BMI >28 kg/m², the M-probe fails to obtain measurements in 16% of cases and produces unreliable results in 50% of cases 1. This is primarily driven by increased skin-to-liver-capsule distance (SCD) that prevents adequate tissue penetration.

Key Technical Differences Between Probes:

• M-probe: Measures at 25-65 mm depth; optimal for patients with SCD <25 mm
• XL-probe: Uses 2.5 MHz transducer; measures at 35-75 mm depth; designed for patients with obesity (BMI >28 kg/m²)

Impact on Diagnostic Accuracy

Measurement Reliability

**The XL-probe dramatically reduces failure rates in obese patients—from 16% with M-probe to only 1.1% with XL-probe (p <0.00005)** 1. Unreliable results also decrease from 50% to 25% 1. This improved reliability is critical because unreliable measurements (IQR/M >30%) translate directly into decreased diagnostic accuracy 1.

Critical Caveat: Different Stiffness Values

Stiffness values obtained with the XL-probe are systematically lower than M-probe values by a median of 1.4 kPa 1. This means:

• You cannot directly compare M-probe and XL-probe measurements
• Using the wrong probe can lead to misclassification of fibrosis stage
• Cutoff values for staging fibrosis differ between probes

Algorithmic Approach to Probe Selection

Based on the strongest guideline evidence 1, follow this decision pathway:

Step 1: Assess Patient Characteristics

• Measure BMI and waist circumference (WC)
• If available, measure skin-to-liver-capsule distance (SCD) by ultrasound

Step 2: Apply Selection Criteria

Use M-probe if:

• BMI ≤35 kg/m² AND WC ≤117 cm
• SCD ≤25 mm
• In this population, M-probe applicability reaches 94.3% with excellent diagnostic accuracy (AUROC 0.89 for fibrosis, 0.96 for cirrhosis) 2

Use XL-probe if:

• BMI >28 kg/m² (especially if >35 kg/m²)
• WC >117 cm
• SCD >25 mm
• Previous M-probe failure or unreliable result

Step 3: The "M-First" Strategy

Recent evidence supports an "M-first" approach with XL-probe backup 3. This means:

1. Start with M-probe in all patients
2. If measurement fails or is unreliable (IQR/M >30%), immediately switch to XL-probe
3. This approach leads to fewer discrepancies in fibrosis staging (OR 2.4) and steatosis assessment (OR 4.8) compared to starting with XL-probe 3

In 81.6% of patients with invalid M-probe measurements, a reliable result can be obtained by switching to XL-probe 4.

Common Pitfalls and How to Avoid Them

Pitfall 1: Using M-probe in All Patients Regardless of Body Habitus

• Consequence: Up to 50% unreliable results in obese patients, leading to missed diagnoses or inappropriate reassurance
• Solution: Measure SCD; if >25 mm, use XL-probe from the start 4, 2

Pitfall 2: Directly Comparing M-probe and XL-probe Values

• Consequence: Misclassification of fibrosis stage due to 1.4 kPa systematic difference
• Solution: Use probe-specific cutoff values; document which probe was used for all follow-up comparisons 1

Pitfall 3: Not Recognizing XL-probe Limitations

• Consequence: False confidence in results despite 25% still having unreliable measurements
• Solution: Always check quality metrics (IQR/M <30%, ≥10 valid measurements) regardless of probe used 1

Pitfall 4: Ignoring the Impact of Obesity on Accuracy

• Consequence: Even with XL-probe, diagnostic accuracy decreases in severe obesity
• Solution: In patients with BMI >35 kg/m², consider MR elastography as the gold standard, which is unaffected by obesity and has only 4.3% failure rate 5

Additional Technical Requirements

Regardless of probe choice:

• Fasting requirement: Minimum 3 hours (not 2 hours as previously recommended) 6
• Quality criteria: IQR/M <30% for reliable results 1
• Measurement depth: Maintain consistent depth (4-4.5 cm) for follow-up studies 7
• Number of measurements: Obtain ≥10 valid measurements and report median value 7

When Probe Selection Still Fails

If both M-probe and XL-probe produce unreliable results:

• Consider MR elastography: Superior performance in obesity, ascites, and can assess entire liver parenchyma 5
• Alternative: Point shear wave elastography (ARFI) has 3-times lower unreliable examination rates (2.1% vs 6.6%) compared to transient elastography 8

Bottom Line for Clinical Practice

The appropriate probe must be selected based on patient body habitus to ensure measurement success and accuracy. Using the M-probe in obese patients leads to unacceptably high failure rates that compromise patient care. The systematic 1.4 kPa difference between probes means incorrect probe selection can change fibrosis staging, affecting decisions about treatment initiation, HCC surveillance, and prognosis. Start with M-probe, but have a low threshold to switch to XL-probe if BMI >28 kg/m², WC >117 cm, or SCD >25 mm 1, 3, 2.